Bladder Related

Surveillance for low-risk non-muscle invasive bladder cancer: A Pilot Study
Principal Investigator: Robert Svatek, MD IRB #:
Department Address: Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229

Contact Person:

Izelda Zarate


Enrollment Notes:  patients with bladder cancer

The target age is: 18years of age

Study Begin and End Date: January 2013- January 2015

Eligibility Criteria:  Men or women with a diagnosis of "superficial" (non-muscle invasive bladder cancer)


Type of Study: Intervention

Funding Source: Cancer Therapy and Research Center
Detailed description of this study
In the U.S., guidelines for following patients with non-muscle invasive bladder cancer indicate that patients should undergo cystoscopy every 3 months for the first 2 years after diagnosis, then every 6 months for the next 2 years, and then yearly. This recommendation is based on expert opinion (Level 4 evidence). The European Association Urology (EAU) recommends a less frequent followup scheme (see Treatment plan below). Although such an approach could considerably decrease costs and burden during the follow-up period by examining patients less frequently, to date these surveillance approaches have never been assessed in a prospective manner.  The goal of the study is to compare these 2 different approaches to surveillance for bladder cancer in terms of progression rates, direct and indirect costs, and patient satisfaction.




Title: Phase III blinded study of immediate post-TURBT instillation of Gemcitabine versus Saline in patients with newly diagnosed or occasionally recurring grade I/II superficial bladder cancer.

Type(s) of Cancer: Bladder Related
Study Phase(s): Phase III
Contact: Epp Goodwin at (210) 450-5798